Exactly, but what would be the NTA per share after the right issue considering the dilution is very significant?
- Forums
- ASX - By Stock
- SGR
- Ann: Appendix 4D & 2023 Half-Year Financial Report
Ann: Appendix 4D & 2023 Half-Year Financial Report, page-22
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SGR (ASX) to my watchlist
|
|||||
Last
49.0¢ |
Change
-0.015(2.97%) |
Mkt cap ! $1.412B |
Open | High | Low | Value | Volume |
50.0¢ | 50.5¢ | 49.0¢ | $1.092M | 2.206M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
65 | 1256409 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 590434 | 39 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
64 | 1355307 | 0.490 |
29 | 921999 | 0.485 |
54 | 1302493 | 0.480 |
25 | 1696196 | 0.475 |
27 | 831077 | 0.470 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 236356 | 28 |
0.500 | 744243 | 35 |
0.505 | 621660 | 17 |
0.510 | 879356 | 25 |
0.515 | 750925 | 21 |
Last trade - 12.02pm 16/07/2024 (20 minute delay) ? |
Featured News
SGR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online